

Form PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DKT. NO.

BAYER 15P4

SERIAL NO.

10/071,248

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

APPLICANT

Jacques Dumas and William J. Scott

FILING DATE

February 11, 2002

GROUP

1625

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date
RO	AA	502,504	8/1/1893	Thoms		
RO	AB	1,742,156	2/31/1922	Fritzky		
RO	AC	2,046,375	7/36	Goldstein et al.		
RO	AD	2,093,265	9/36	Coffby et al.		
RO	AE	2,288,422	6/42	Rohm		
RO	AF	2,649,476	8/18/53	Martin		
RO	AG	2,683,082	7/54	Hill et al.		
RO	AH	2,722,544	11/1/55	Martin		
RO	AI	2,745,874	5/56	Schetty et al.		
RO	AJ	2,781,330	2/57	Downey		
RO	AK	2,797,214	6/25/57	Werner Bossard		
RO	AL	2,867,659	1/59	Model et al.		
RO	AM	2,877,268	3/59	Applegate et al.		
RO	AN	2,960,488	11/60	Tamblyn et al.		
RO	AO	2,973,386	2/61	Weldon		
RO	AP	3,151,023	9/64	Martin		
RO	AQ	3,200,035	8/65	Martin et al.		
RO	AR	3,230,141	1/66	Frick et al.		
RO	AS	3,424,760	01/28/69	Helsley et al.		
RO	AT	3,424,761	01/28/69	Helsley et al.		
RO	AU	3,424,762	01/28/69	Helsley et al.		
RO	AV	3,547,940	12/15/70	Brantley		
RO	AW	3,646,059	02/29/72	Brantley		
RO	AX	3,689,550	9/72	Schellenbaum et al.		
RO	AY	3,743,498	7/3/73	Brantley		
RO	AZ	3,754,887	08/28/73	Brantley		
RO	BA	3,823,161	07/09/74	Lesser		
RO	BB	3,828,001	8/74	Broad et al.		
RO	BC	3,860,645	1/9/75	Nikawitz		
RO	BD	3,990,879	11/9/1976	Soper		
RO	BE	4,001,256	1/4/97	Callahan et al.		
RO	BF	4,009,847	3/1/77	Aldrich et al.		
RO	BG	4,042,372	8/16/1977	Harper		
RO	BH	4,062,861	12/13/77	Yukinaga et al.		
RO	BI	4,071,524	01/31/78	Banitt		
RO	BJ	4,111,680	09/05/78	Yukinaga et al.		


RECEIVED
OCT 24 2002
TECH CENTER 1600/2800

OFFICE
JUN 10 2002
JC98

10/091248

RO	BK	4,161,683	09/65/78	Singer			
RO	BL	4,116,671	09/26/78	Yukinaga et al.			
RO	BM	4,173,637	11/79	Nishiyama et al.			
RO	BN	4,173,638	11/79	Nishiyama et al.			
RO	BO	4,183,854	1/80	Crossley			
RO	BP	4,212,981	07/15/80	Yukinaga et al.			
RO	BQ	4,240,820	12/23/80	Dickore et al.			
RO	BR	4,405,644	9/20/83	Kabbe et al.			
RO	BS	4,410,697	10/18/83	Török et al.			
RO	BT	4,437,878	03/20/84	Acker et al.			
RO	BU	4,468,380	8/28/84	O'Doherty et al.			
RO	BV	4,473,579	9/25/84	Devries et al.			
RO	BW	4,511,571	4/85	Böger et al.			
RO	BX	4,514,571	04/30/85	Nakai et al.			
RO	BY	4,526,997	7/2/85	O'Doherty et al.			
RO	BZ	4,623,662	11/18/86	De Vries			
RO	CA	4,643,849	02/17/87	Hirai et al.			
RO	CB	4,740,520	4/88	Hallenbach et al.			
RO	CC	4,760,063	7/26/88	Hallenbach et al.			
RO	CD	4,808,588	02/28/89	King			
RO	CE	4,820,871	4/89	Kissener et al.			
RO	CF	4,863,924	9/89	Haga et al.			
RO	CG	4,983,605	1/91	Kondo et al.			
RO	CH	4,985,449	1/15/91	Haga et al.			
RO	CI	5,036,072	7/91	Nakajama et al.			
RO	CJ	5,059,614	10/22/91	Lepage et al.			
RO	CK	5,098,907	3/92	Kondo et al.			
RO	CL	5,130,331	07/14/92	Pascual			
RO	CM	5,162,360	11/10/92	Creswell et al.			
RO	CN	5,185,358	2/9/1993	Creswell			
RO	CO	5,312,820	5/17/94	Ashton et al.			
RO	CP	5,319,099	6/7/94	Kamata et al.			
RO	CQ	5,399,566	3/21/95	Katano et al.			
RO	CR	5,423,905	6/95	Fringeli			
RO	CS	5,429,918	7/4/1995	Seto et al.			
RO	CT	5,432,468	7/11/95	Moriyama et al.			
RO	CU	5,470,882	11/95	Dixon et al.			
RO	CV	5,500,424	3/19/96	Nagamine et al.			
RO	CW	5,508,288	04/16/96	Forbes et al.			
RO	CX	5,597,719	1/28/97	Freed et al.			
RO	CY	5,696,138	12/9/97	Olesen et al.			
RO	CZ	5,698,581	12/16/97	Kleemann et al.			
RO	DA	5,773,459	06/30/98	Tang et al.			
RO	DB	5,780,483	7/14/98	Widdowson et al.			
RO	DC	5,780,483	7/14/98	Widdowson et al.			
RO	DD	5,807,891	9/15/98	Bold et al.			

RECEIVED
OCT 24 2002
TECH CENTER 1830/2900



10/091248

RO	DE	5,814,646	9/29/1998	Heinz				
RO	DF	5,886,044	3/23/99	Widdowson et al.				
RO	DG	5,891,895	4/6/99	Shiraishi et al.				
RO	DH	5,908,865	6/1/1999	Doi et al.				
RO	DI	5,965,573	10/12/99	Petrie et al.				
RO	DJ	6,004,965	12/21/99	Breu et al.				
RO	DK	6,005,008	12/21/99	Widdowson et al.				
RO	DL	6,020,345	2/1/00	Vacher et al.				
RO	DM	6,040,339	3/21/00	Yoshida et al.				
RO	DN	6,080,763	6/27/2000	Regan et al.				
RO	DO	6,093,742	7/25/00	Salituro et al.				
RO	DP	6,133,319	10/17/00	Widdowson				
RO	DQ	6,150,415	11/21/00	Hammock et al.				
RO	DR	6,174,901B1	1/16/01	Mantlo et al.				
RO	DS	6,178,399B1	1/23/01	Takebayashi et al.				
RO	DT	6,180,675B1	1/30/01	Widdowson et al.				
RO	DU	6,187,799B1	2/13/01	Wood et al.				
RO	DV	6,211,373B1	4/3/01	Widdowson et al.				
RO	DW	6,218,539B1	4/17/01	Widdowson et al.				
RO	DX	6,242,601B1	6/5/01	Breu et al.				
RO	DY	6,262,113B1	7/17/01	Widdowson et al.				
RO	DZ	6,271,261B1	8/7/01	Widdowson				
RO	EA	6,333,341B1	12/25/01	Mantlo et al.				
RO	EB	6,339,045B1	1/15/02	Kanno et al.				

RECEIVED
OCT 24 2002
TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
RO	EC	90/02112	3/8/90	WO			
RO	ED	93/18028	09/16/93	WO			
RO	EE	93/24458	12/9/93	WO			
RO	EF	94/14801	07/07/94	WO			
RO	EG	94/22807	10/13/94	WO			
RO	EH	94/18170	08/18/94	WO			
RO	EI	94/25012	11/10/94	WO			
RO	EJ	95/02591	01/26/95	WO			
RO	EK	95/07922	03/23/95	WO			
RO	EL	95/13067	05/18/95	WO			
RO	EM	95/31451	11/23/95	WO			
RO	EN	95/33458	12/14/95	WO			
RO	EO	96/10559	4/11/96	WO			
RO	EP	96/25157 A1	8/22/96	WO			
RO	EQ	96/40673	12/19/96	WO			
RO	ER	96/40675 A1	12/19/96	WO			
RO	ES	97/17329	5/15/97	WO			



12/09/2002

IVED

RO	ET	97/29743	8/21/97	WO				
RO	EU	97/30992	8/28/97	WO				
RO	EV	97/40028 A1	10/30/97	WO				4 2002
RO	EW	97/49400	12/31/97	WO				
RO	EX	97/49399	12/31/97	WO				
RO	EY	97/45400	12/4/97	WO				
RO	EZ	98/17267	4/30/98	WO				
RO	FA	98/22103	5/28/1998	WO				
RO	FB	98/22432	5/28/98	WO				
RO	FC	98/52558	11/26/98	WO				
RO	FD	98/52559	11/26/98	WO				
RO	FE	99/00357	1/7/99	WO				
RO	FF	99/00370	1/7/99	WO				
RO	FG	99/23091	5/14/99	WO				
RO	FH	99/24398	5/20/99	WO				
RO	FI	99/32106	7/1999	WO				
RO	FJ	99/32110	7/1/99	WO				
RO	FK	99/32111	7/1/1999	WO				
RO	FL	99/32436	7/1/99	WO				
RO	FM	99/32437	7/1/99	WO				
RO	FN	99/32455	7/1/1999	WO				
RO	FO	99/32463	7/1/99	WO				
RO	FP	99/33458	7/8/99	WO				
RO	FQ	99/40673	8/12/99	WO				
RO	FR	00/17175	3/30/2000	WO				
RO	FS	00/43366A1	01/20/2000	WO				
RO	FT	00/43384	7/27/2000	WO				
RO	FU	00/55139	9/21/2000	WO				
RO	FV	00/55152	9/21/2000	WO				
RO	FW	0016371A1	3/5/80	EP				
RO	FX	0 405 233	1/91	EP				
RO	FY	0116932	8/29/84	EP				
RO	FZ	242666	10/28/87	EP				
RO	GA	335156	03/11/89	EP				
RO	GB	371876	11/28/89	EP				
RO	GC	425443A1	2/5/91	EP				
RO	GD	459887	05/28/91	EP				
RO	GE	676395	7/17/1996	EP				
RO	GF	0202538A1	11/26/86	EP				
RO	CG	860433A1	8/26/98	EP				
RO	GH	0 523 437	5/31	Germany				
RO	GI	0 511 468	10/30	Germany				
RO	GJ	0 487 014	12/29	Germany				
RO	GK	0 253 997	2/88	East Germany				
RO	GL	2436179A1	2/6/1975	DE				

JUN 10 2002

10/071248

RO	GM	2436179C2	2/6/75	DE				
RO	GN	25 01 648	7/24/75	DE				
RO	GO	35 40 377 A1	11/14/85	DE				
RO	GP	35 29 247 A1	8/20/85	DE				
RO	GQ	3305866A1	02/19/83	DE				
RO	GR	3 532 47	3/91	Japan				
RO	GS	8 031841	11/19/96	Japan				
RO	GT	44 2569	2/69	Japan				
RO	GU	10-306078	11/17/98	Japan				
RO	GV	50-149668	11/75	Japan				
RO	GW	50-76072	6/75	Japan				
RO	GX	50-77375	6/75	Japan				
RO	GY	51 063170	1/6/76	Japan				
RO	GZ	51-80862	7/76	Japan				
RO	HA	53 086033	7/29/78	Japan				
RO	HB	55 98152	7/80	Japan				
RO	HD	55-124763	9/80	Japan				
RO	HE	55-162772	12/80	Japan				
RO	HF	0 771 333	3/57	Great Britain				
RO	HG	0 828 231	10/56	Great Britain				
RO	HH	0 921 682	3/63	Great Britain				
RO	HI	1,590,870	06/10/81	Great Britain				
RO	HJ	1 457 172	9/66	France				
RO	HK	2,146,707	10/12/95	Canada				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

RO	HL	Caplus 86:72448, Abstract JP 57053785, Pyridine derivatives, Maeda Ryozyo et al., November 15, 1982
RO	HM	Caplus 84:180049, Abstract JP 56029871, Hamada Yoshinori et al., July 10, 1981
RO	HN	Caplus 84:43857, Abstract JP 58021626, Maeda Ryozyo et al., May 2, 1983
RO	HO	Caplus 95:61995, Abstract JP 55162772, Substituted acetic derivatives, Shionogi & Co., May 23, 1980
RO	HP	Abstract of EP 202,538
RO	HQ	Abstract of DE 3305866 (EP equivalent 116,932)
RO	HR	Abstract of EP 116,932
RO	HS	Abstract of EP 16,371
RO	HT	Abstract of EP 4931A equivalent 4,240,820)
RO	HU	Abstract of EP 676,395 (U.S. equivalent 5,698,581)
RO	HV	Abstract WO 9822103, Hedge 28 May 1998
RO	HW	Chemical Abstract, Vol. 116, No. 21, 25 May 1992, pages 741-742
RO	HX	Tarzia, G. et al., "Whythesis and anit-inflammatory properties of some pyrrolo(1H,3H)[3,4]pyrimidin-2-ones and pyrrolo(1H,3H)[3,4-d]pyrimidin-2-ones and pyrrolo(1H,3H)-pyrimidin-2-ones. Chemical Abstracts. 27 August 1979, No. 74558p; page 594.
RO	HY	White, A. D., et al., "Heterocyclic Ureas: Inhibitors of Acyl-CoA:Cholesterol O-Acyltransferase as Hypocholesterolemic Agents," June 6, 1996, pages 4382-95.



10/071248

RO	HZ	Audia, James E., et al., "Potent, Selective Tetraphdro- β -carboline Antagonists of the Serotonin 2B ₅ HT _{2B} Contractile Receptor in the Rat Stomach Fundus," January 22, 1996, pages 2773-80.
R	IA	Forbes, Ian T., "N-(1-Methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea: A Novel, High-Affinity 5-HT _{2B} Receptor Antagonist," March 17, 1995, pages 855-57.
R	IB	Boulton, A. J., et al., "Heterocyclic Rearrangements. Part X. ¹ A Generalised Monocyclic Rearrangement," 1967, 2005-07.
RO	IC	W. Kolch, et al., "Raf-1 protein kinase is required for growth of induced NIH/3T3 cells," Letters to Nature, vol. 349, January 31, 1991, page 226-28.
RO	ID	M. Fridman, et al., "The Minimal Fragments of c-Raf-1 and NF1 That Can Suppress v-Ha-Ras-Induced Malignant Phenotype," The Journal of Biological Chemistry, vol. 269, no. 48, December 2, 1994, pages 30105-108.
RO	IE	G. L. Bolton, et al., Chapter 17. Ras Oncogene Directed Approaches in Cancer Chemotherapy, Annual Reports In Medicinal Chemistry, vol. 29, 1994, pages 165-74.
RO	IF	J. L. Bos, "ras Oncogenes in Human Cancer: A Review," Cancer Research, vol. 49, September 1, 1989, pages 4682-89.
RO	IG	Michaelis, Justus, Liebigs Ann. Chem. (JLACBF) 397, 1913, 143.
RO	IH	B. P. Monia, et al., "Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase," Nature Medicine, vol. 2, No. 6, June 1996, pages 668-75.
RO	II	Lee, et al., Bicyclic Imidazoles as a Novel Class of Cytokine Biosynthesis Inhibitors," N.Y. Academy of Science, 1993, pages 149-70.
RO	IJ	F. Lepage, et al., "New N-aryl isoxazolecarboxamides and N-isoxazolybenzamides as anticonvulsant agents," Eur. J. Med. Chem, vol. 27, 1992, pages 581-93.
RO	IK	Ridley, et al., "Actions of IL-1 are Selectively Controlled by p38 Mitogen-Activated Protein Kinase," The American Association of Immunologists, 1997, page 3165-73.
RO	IL	N. S. Magnuson, et al., "The Raf-1 serine/threonine protein kinase," Cancer Biology, vol. 5, 1994, pages 247-253.
RO	IM	G. Daum, et al., The ins and outs of Raf Kinases,," TIBS 19, November 1994, pages 474-80.
RO	IN	Grant, A.M. et al.: "Hypotensive thiadiazoles" J. Med. Chem. (1972), 15(10), 1082-4.
RO	IO	Russo, F. et al. "Synthesis of 2,6-substituted derivatives of 5H-1,3,4-thiadiazolo'3,2-a'-s triazine-5,7-dione" FARMACO, ED.SCI. (1978), 33(12), 972-83
RO	IP	Joseph T. Bruder and Imre Kovesdi, "Adenovirus Infection Stimulates the Raf/MAPK Signaling Pathway and Induces Interleukin-8 Expression, May 17, 1996, pp. 198-404.
RO	IQ	Foussard-Blanpin, Odette: "Comparative pharmacodynamic study of variously substituted carboxamides of the central nervous system" Ann. Pharm. Fr. (1982), 40 (4), 339-50
RO	IR	Kubo, Hiroshi et al. "Herbicidal activity of 1,3,4-thiadiazole derivatives" J. Agr. Food Chem. (1970) , 18(1), 60-5
RO	IS	Avruch et al., "Raf meets Ras: completing the framework of a signal transduction pathway", TIBS 19; July 1994; pp. 279-2823.
	IT	
	IU	
	IV	
	IW	
	IX	
	IY	
	IZ	

RECEIVED
 OCT 24 2002
 TECH CENTER 160012800

Examiner R. Desai Date Considered 12-9-2002

*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.